Eczema drug trial failure sinks AnaptysBio, boosts rival Dermira

Shares of AnaptysBio (ANAB) plunged in late morning trading after the company disclosed that its Phase 2b trial for etokimab in atopic dermatitis failed to meet its primary endpoint. Shares of rival... To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id2991229/-Eczema-drug-trial-failure-sinks-AnaptysBio-boosts-rival-Dermira)

Sign Up

Get the InvestingChannel
Free e-Letter Today

Learn More

Independent market opinion, analysis and ideas - delivered every business day

Premium market opinions, analysis, and ideas - delivered every business day

Editor's Picks